Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_29_2294 - Advanced Prostate Imaging of Recurrent Cancer After Radiation Therapy (PICs): Interim Results of a Prospective, Multi-Center Trial

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Advanced Prostate Imaging of Recurrent Cancer After Radiation Therapy (PICs): Interim Results of a Prospective, Multi-Center Trial
W. Liu1, H. T. Chung2, P. Chung3, K. Zukotynski4, U. Metser5, I. Rachinsky6, R. Wolfson7, S. Archer1, L. Emmett8, and G. S. Bauman1; 1London Regional Cancer Program, London, ON, Canada, 2Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, 3Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 4Hamilton Health Sciences Centre, Hamilton, ON, Canada, 5Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 6London Health Sciences Centre, London, ON, Canada, 7Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 8St. Vincent's Hospital, Sydney, Australia

Purpose/Objective(s): [18F]-DCFPyL is a second generation positron emission tomography (PET) probe targeting PSMA - a trans-membrane protein overexpressed in prostate cancer. PICs seeks to evaluate [18F]-DCFPyL PET/CT in restaging men with biochemical failure (BF) after primary radiation therapy.

Materials/Methods: PICs (NCT02793284) is a prospective, single arm study conducted at four cancer centers in Ontario of men with BF (Phoenix definition) after primary radiation for localized (T1/T2, Gleason ≤8, PSA≤20) prostate cancer. Participants undergo conventional imaging (CI: computed tomography (CT) thorax/ abdomen/ pelvis, bone scan, and multiparametric MRI pelvis) followed by [18F]-DCFPyL PET/CT (PET). PET was reported by nuclear medicine physicians at each Cancer Center with central review. In cases of disagreement a third read is specified by the protocol. Primary endpoint is the proportion of men with metastatic disease detected by PET compared to CI. Secondary endpoints include number of lesions outside the prostate detected by PET compared to CI, and changes in patient management plan based on results of PET vs. CI.

Results: Since opening in January 2017, 50 of a planned 80 patients have been accrued; the first 35 patients are reported here. At enrollment, median age was 75, median PSA 7.1, median PSA doubling time was 11.0 months, and median time from end of definitive radiation treatment to BF was 65.4 months. Stage and grade at the time of definitive radiotherapy was T1 (18/35, 51%) or T2 (17/35, 49%) and Gleason 6 (9/35, 26%), 7(25/35, 71%), or 8 (1/35, 3%). Previous treatment included external beam radiotherapy (24/35, 69%) or brachytherapy (11/35, 31%). Overall, any site of recurrence was identified in 33/35 (94%) men by both CI and PET. Extra-prostatic metastases were detected in 10/35 (29%) patients by CI and in 13/35 (37%) by PET. Isolated intra-prostatic recurrence was identified by CI in 21/35 (60%); PET detected additional, unrecognized extra-prostatic metastases in 4/21 (19%). A change in management plan based on PET vs. CI occurred in 17/35 men (49%). Changes included the addition of salvage RT (8/17, 47%), ADT (4/17, 24%), biopsy (3/17, 18%), and HIFU (1/17, 6%).

Conclusion: For men with BF after primary RT, [18F]-DCFPyL PET/CT detects additional sites of disease that result in changes in management compared to CI. Identification of extra-prostatic metastases among men where CI identifies isolated intra-prostatic recurrence suggests a role for [18F]-DCFPyL PET/CT in optimizing selection for local salvage treatments. Updated results will be presented.

Author Disclosure: W. Liu: None. H.T. Chung: Independent Contractor; Sunnybrook Health Sciences. P. Chung: Research Grant; Sanofi. K. Zukotynski: Independent Contractor; Hamilton Health Sciences Centre. U. Metser: Independent Contractor; University Health Network. I. Rachinsky: Independent Contractor; London Health Sciences Centre. R. Wolfson: Independent Contractor; Sunnybrook Health Sciences Centre. S. Archer: None. G. Bauman: Independent Contractor; London Health Sciences Centre. Chair/Chief of Oncology; London Health Sciences Centre.

Send Email for Wei Liu


Assets

SU_29_2294 - Advanced Prostate Imaging of Recurrent Cancer After Radiation Therapy (PICs): Interim Results of a Prospective, Multi-Center Trial



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Advanced Prostate Imaging of Recurrent Cancer After Radiation Therapy (PICs): Interim Results of a Prospective, Multi-Center Trial